

**IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF OHIO
EASTERN DIVISION**

**IN RE NATIONAL PRESCRIPTION
OPIATE LITIGATION**

CASE NO. 1:17-MD-2804

**THIS DOCUMENT RELATES TO:
“All Cases”**

)
) **David R. Cohen**
) **Randi S. Ellis**
) **Hon. David R. Herndon**
)
) **FEE PANEL ORDER NO. 27**
) **REGARDING APPLICATION**
) **DEADLINE FOR TEVA/ALLERGAN**
) **CONTINGENCY FEE AWARDS**

As of the date of this Order, 25 Settling States have entered into Consent Judgments with Teva Pharmaceutical Industries Ltd. and Allergan Finance, LLC.,¹ thereby making effective the Teva and Allergan Fee Agreements.² Counsel has been able to submit Teva/Allergan Contingency Fee Fund Applications since June 12, 2023. Accordingly, the Fee Panel hereby sets **December 14, 2023**, as the deadline for submission of applications for awards from the Teva and Allergan Contingency Fee Funds.

IT IS SO ORDERED.

/s/ **David R. Cohen**
Randi S. Ellis
David R. Herndon
FEE PANEL

Dated: November 30, 2023

¹ See <https://nationalopioidsettlement.com/state-participation-status/>

² See, e.g., Teva Global Opioid Settlement Agreement, Exh R. at R-1 (“This Fee Agreement becomes effective on the Effective Date of the Teva Agreement and Allergan Agreement or the date that the Consent Judgments anticipated under the Teva Agreement and Allergan Agreement become final in 25 Settling States (whichever is later).”).